Scalper1 News
As the new year turns, investors, physicians and patients alike will be waiting eagerly for Bristol-Myers Squibb to report results from the latest trial of drug candidate nivolumab. The trial, studying patients with a virulent disease called squamous non-small-cell lung cancer, is just a phase two trial, and it normally requires three rounds before a company will file for approval. But previous results were so strong, and the other Scalper1 News
Scalper1 News